Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials
Diabetes, Obesity and Metabolism Dec 24, 2021
Jódar E, Romera I, Wang Q, et al. - By conducting post hoc analyses, data were pooled from randomized, phase 3 studies (n=6) assessing the relationship between treatment with dulaglutide 1.5 mg once weekly and glycaemic variability (GV) in adult patients with type 2 diabetes mellitus (T2D).
Dulaglutide for T2D administered as monotherapy or added to oral glucose-lowering medication, without concomitant insulin treatment, was found to be potentially linked with a decrease in GV.
A reduction in GV to a greater degree was achieved with dulaglutide vs insulin glargine.
When added to insulin glargine, dulaglutide treatment was shown to be related to greater reductions in GV than insulin glargine alone.
Observations from this study may be clinically relevant as decreased GV may be linked with better outcomes.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries